[Ip-health] support letter from Brazilian organizations and patients groups for IGWG
marcela.vieira@conectas.org
marcela.vieira@conectas.org
Thu Apr 24 14:58:04 2008
--
--
[ Picked text/plain from multipart/alternative ]
Dear all,
As you may already know, there was a meeting in S=C3=A3o Paulo held in
February on innovation, IP and access to medicines (Latin Conference
for Patient Associations on Access to Medicines & Public Policy). The
meeting was organized by cancer patient groups in Brazil and
co-sponsored by Consumer Advocare Network, and the Alian=C3=A7a Latina de
Pacientes com Doen=C3=A7as Hematologicas (Latin American Alliance of
Patients with Hematological Diseases, "Alianza Latina=E2=80=9D).
As a member of the Working Group on IP (GTPI) from Rebrip (Brazilian
Network for the integration of peoples), we were banned from the list
of participants. However, one colleague was able to attend part of the
debate, which focused on the relevance of IP rules in the development
of innovation, and an important discussion against compulsory
licensing, etc.
At this meeting, they circulated a letter about IGWG issues, which
mainly asks WHO not to proceed with recommending changes to
international patent protection. The letter is available at:
http://www.patientsandpatents.com/index.php/us/positions/patient_declaratio=
n_on_medical_innovation
[1]
In response, we are collecting signatures for another letter of
Patients Groups and Civil Society organizations that asks for the
revision of the rules regulating Innovations and the Access to the
fruits of Innovations (so far we got support from 102 organizations
from developing countries in Latin America, Africa and Asia). In
addition, we are asking for support from organizations and patient
groups in other countries, especially those in the southern
hemisphere.
Our letter is available below, in Portuguese, English and Spanish,
as well as a list of all organizations that have already signed it
(the letter is also attached).
Signatures should be sent to the following addresses:
marcela@conectas.org and claudio@abiaids.org.br
***************************************************************************=
***************************************************************************=
*****************
DECLARA=C3=87=C3=83O CONJUNTA DE ORGANIZA=C3=87=C3=95ES DA SOCIEDADE CIVIL=
E GRUPOS
DE PACIENTES SOBRE SA=C3=9ADE P=C3=9ABLICA, INOVA=C3=87=C3=83O M=C3=89DICA =
E ACESSO A
MEDICAMENTOS
=09Tendo em vista que:
=091. A sa=C3=BAde =C3=A9 um direito humano fundamental, condi=C3=A7=C3=
=A3o
essencial para a dignidade humana e pleno exerc=C3=ADcio da cidadania;
=092. O modelo dominante de inova=C3=A7=C3=A3o m=C3=A9dica, refor=C3=A7=
ado pela
implementa=C3=A7=C3=A3o do Acordo sobre Direitos de Propriedade Intelectual
relacionados ao com=C3=A9rcio (TRIPS) da Organiza=C3=A7=C3=A3o Mundial do
Com=C3=A9rcio, =C3=A9 baseado em incentivos patent=C3=A1rios geradores de
monop=C3=B3lios, pre=C3=A7os altos como retorno sobre investimentos e
perspectivas de mercado nos pa=C3=ADses desenvolvidos;
=093. Dados do mercado mundial de medicamentos [1] mostram que os
pa=C3=ADses em desenvolvimento representam menos de 15 % do mercado
mundial de medicamentos;
=094. Doen=C3=A7as que atingem desproporcionalmente os pa=C3=ADses em
desenvolvimento n=C3=A3o s=C3=A3o alvo de pesquisa e desenvolvimento (P&D) =
e
inova=C3=A7=C3=B5es significativas, apesar da crescente prote=C3=A7=C3=A3o =
patent=C3=A1ria
nesses pa=C3=ADses;
=095. Recente relat=C3=B3rio de uma comiss=C3=A3o da Organiza=C3=A7=C3=
=A3o Mundial
da Sa=C3=BAde chamado Comiss=C3=A3o sobre Propriedade Intelectual, Inova=C3=
=A7=C3=A3o
e Sa=C3=BAde P=C3=BAblica (CIPIH) [[2]] apontou que a propriedade intelectu=
al
n=C3=A3o =C3=A9 um instrumento adequado para desenvolver as tecnologias
necess=C3=A1rias para responder aos problemas de sa=C3=BAde espec=C3=ADfico=
s dos
pa=C3=ADses em desenvolvimento;
=096. A exist=C3=AAncia nas legisla=C3=A7=C3=B5es nacionais das flexibi=
lidades
do Acordo sobre Direitos de Propriedade Intelectual relacionados ao
Com=C3=A9rcio (TRIPS) da Organiza=C3=A7=C3=A3o Mundial do Com=C3=A9rcio (OM=
C) para a
prote=C3=A7=C3=A3o da sa=C3=BAde p=C3=BAblica, como a licen=C3=A7a compuls=
=C3=B3ria, n=C3=A3o
significa sua efetiva implementa=C3=A7=C3=A3o e pa=C3=ADses fazendo uso des=
sas
flexibilidades vem sofrendo amea=C3=A7as de retalia=C3=A7=C3=B5es por parte=
de
alguns pa=C3=ADses desenvolvidos.
=09Consideramos de suma import=C3=A2ncia a atual discuss=C3=A3o no =C3=A2mb=
ito do
Grupo Intergovernamental de Trabalho sobre Sa=C3=BAde P=C3=BAblica, Inova=
=C3=A7=C3=A3o
e Propriedade Intelectual (IGWG), da Organiza=C3=A7=C3=A3o Mundial da Sa=C3=
=BAde
(OMS) e solicitamos:
=09=C2=B7 Uma revis=C3=A3o das regras que regem a inova=C3=A7=C3=A3o e o =
acesso ao
fruto desta inova=C3=A7=C3=A3o para que as necessidades em sa=C3=BAde dos p=
a=C3=ADses
em desenvolvimento sejam consideradas na agenda internacional de P&D.
=09=C2=B7 Que o IGWG encontre solu=C3=A7=C3=B5es sustent=C3=A1veis para q=
ue os
medicamentos, vacinas e diagn=C3=B3sticos existentes e novos sejam
efetivamente acess=C3=ADveis para todos aqueles que deles precisem nos
pa=C3=ADses em desenvolvimento.
=09=C2=B7 Que o IGWG enfatize a import=C3=A2ncia do apoio da OMS na
implementa=C3=A7=C3=A3o efetiva das flexibilidades do TRIPS pelos pa=C3=ADs=
es que
delas precisem para garantir o acesso a medicamentos.
=09=C2=B7 Que o IGWG busque novos mecanismos de incentivos =C3=A0 inova=
=C3=A7=C3=A3o
em sa=C3=BAde, levando em considera=C3=A7=C3=A3o a garantia do acesso no fu=
turo.
Pre=C3=A7os altos como solu=C3=A7=C3=A3o para o custeio da inova=C3=A7=C3=
=A3o n=C3=A3o =C3=A9
solu=C3=A7=C3=A3o.
=09=C2=B7 A manuten=C3=A7=C3=A3o e amplia=C3=A7=C3=A3o da participa=C3=A7=
=C3=A3o das
organiza=C3=A7=C3=B5es da sociedade civil e de pacientes, sobretudo do Sul,
nas negocia=C3=A7=C3=B5es travadas no IGWG, considerando com muita aten=C3=
=A7=C3=A3o
os conflitos de interesse que possam existir nessas organiza=C3=A7=C3=B5es.
[1] Dados aproximados IMS website
[2] http://www.who.int/intellectualproperty/en/ [2]
=09Assinatura das organiza=C3=A7=C3=B5es da sociedade civil e grupos de
pacientes:
=09************************************************************************=
***************************************************************************=
***************************************************************************=
***********
JOINT DECLARATION OF CIVIL SOCIETY ORGANIZATIONS AND PATIENTS GROUPS
ON PUBLIC HEALTH, MEDICAL INNOVATION AND ACCESS TO MEDICINES
=09Considering that:
=091. Health is a fundamental human right and a necessary condition for
human dignity and for the full exercise of citizenship.
=092. The dominant model of medical innovation, reinforced by the
implementation of the Trade-Related Aspects on Intellectual Property
Rights (TRIPS) agreement of the World Trade Organization, is based on
patent incentives that create monopolies, high prices as return on
investment and market perspectives in developed countries.
=093. Data on the world pharmaceutical market[1] show that developing
countries represent less than 15% of the world medicines sales.
=094. Diseases that disproportionately affect developing countries are
not the targets of significant Research and Development (R&D)
activities and innovations, despite the increase of patent protections
in these countries.
=095. A recent report of a World Health Organization commission called
Commission on Intellectual Property, Innovation and Public Health
(CIPIH)[2] showed that intellectual property is not an adequate
instrument to ensure the development of the technology necessary to
respond to the specific health problems of developing countries.
=096. The incorporation into national legislation of the flexibilities
foreseen in the WTO TRIPS Agreement, such as compulsory licenses, with
the goal of protecting public health does not guarantee the effective
implementation of these mechanisms and countries making use of these
flexibilities are currently undergoing threats of retaliations from
some developed countries.
=09We consider to be of utmost importance the current discussion in the
Intergovernmental Working Group on Public Health, Innovation and
Intellectual Property (IGWG) of the World Health Organization (WHO)
and we request:
=09=C2=B7 A revision of the rules regulating Innovations and
the Access to the fruits of Innovations so that the health needs of
developing countries be included in the international agenda of
innovation.
=09=C2=B7 That the IGWG find sustainable solutions so that
existing and new medicines, vaccines and diagnostic tools be
accessible to all those who need them in developing countries.
=09=C2=B7 That the IGWG emphasizes the importance of the
WHO=E2=80=99s support in the effective implementation of the TRIPS
flexibilities by countries that need them to guarantee access to
medicines.
=09=C2=B7 That the IGWG seeks out new incentive mechanisms for
innovation in health, taking into consideration the importance of
guaranteeing access in the future. High prices as a solution to pay
for the cost of innovation is not a solution.
=09=C2=B7 That the participation of civil society and patient
organizations, especially those from the Global South, in negotiations
held in the IGWG be maintained and expanded, taking into careful
consideration the conflicts of interest that may exist within these
organizations.
[1] Data estimates taken from the IMS website.
[2] http://www.who.int/intellectualproperty/en/ [3]
Signature of civil society organizations and patient groups:
=09************************************************************************=
***************************************************************************=
***************************************************************************=
********************
DECLARACI=C3=93N CONJUNTA DE LAS ORGANIZACIONES DE LA SOCIEDAD CIVIL Y
GRUPOS DE PACIENTES SOBRE SALUD P=C3=9ABLICA, INOVACI=C3=93N M=C3=89DICA Y =
ACCESO
A LOS MEDICAMENTOS
=09Considerando que:
=091. La salud es un derecho humano fundamental y una condici=C3=B3n
esencial para la dignidad humana y para el ejercicio pleno de los
ciudadanos.
=092. El modelo dominante de la innovaci=C3=B3n m=C3=A9dica, reforzado por =
la
implementaci=C3=B3n del Acuerdo sobre los ADPIC, es basado sobre los
incentivos patentarios que crean monopolios, altos precios como un
retorno para las inversiones y perspectivas de mercado en pa=C3=ADses
desarrollados.
=093. Datos del mercado farmac=C3=A9utico mundial[1] evidencian que los
pa=C3=ADses en desarrollo representan menos de 15% de las ventas mundiales
de medicamentos.
=094. Enfermedades que afectan desproporcionalmente a los pa=C3=ADses en
desarrollo no son diana de las actividades de Investigaci=C3=B3n y
Desarrollo (I&D) e Innovaci=C3=B3n significativa, a pesar del aumento de
protecciones patentarias en eses pa=C3=ADses.
=095. Un reciente informe de una comisi=C3=B3n de la Organizaci=C3=B3n Mund=
ial
de la Salud =E2=80=93 Comisi=C3=B3n sobre Propiedad Intelectual, Innovaci=
=C3=B3n y
Salud P=C3=BAblica (CIPIH)[2] - se=C3=B1al=C3=B3 que la propiedad intelectu=
al no
es un instrumento adecuado para asegurar el desarrollo de la
tecnolog=C3=ADa necesaria para atender a problemas espec=C3=ADficos de salu=
d
en los pa=C3=ADses en desarrollo.
=096. La presencia en las legislaciones nacionales de las
flexibilidades del Acuerdo sobre los Aspectos de los Derechos de la
Propiedad Intelectual relacionados al Comercio (Acuerdo sobre los
ADPIC o TRIPS) de la Organizaci=C3=B3n Mundial del Comercio (OMC) para la
protecci=C3=B3n de la salud p=C3=BAblica, tales como licencias obligatorias=
,
no garantiza la implementaci=C3=B3n efectiva de esos mecanismos. Los
pa=C3=ADses que hacen uso de esas flexibilidades vienen sufriendo amenazas
de retaliaciones por parte de algunos pa=C3=ADses desarrollados.
=09Consideramos extremamente importante la discusi=C3=B3n actual en el
Grupo Intergubernamental de Salud P=C3=BAblica, Innovaci=C3=B3n y Propiedad
Intelectual (IGWG) de la Organizaci=C3=B3n Mundial de la Salud (OMS) y
solicitamos:
=09=C2=B7 Una revisi=C3=B3n de las reglas que regulan ls
Innovaci=C3=B3n y el Acceso a los frutos de las Innovaciones, para que las
necesidades de salud de los pa=C3=ADses en desarrollo sean consideradas en
la agenda internacional Investigaci=C3=B3n y Desarrollo .
=09=C2=B7 Que el IGWG encuentre soluciones sostenibles para
que los medicamentos, vacunas y m=C3=A9todos de diagn=C3=B3stico, nuevos y
existentes est=C3=A9n efectivamente accesibles en todos los pa=C3=ADses en
desarrollo que los necesitan.
=09=C2=B7 Que el IGWG enfatize la importancia del apoyo de la
OMS en la implementaci=C3=B3n efectiva de las flexibilidades del ADPIC por
los pa=C3=ADses que de ellas necesiten para garantizar el acceso a los
medicamentos.
=09=C2=B7 Que el IGWG busque nuevos mecanismos de incentivo
para la innovaci=C3=B3n en salud, teniendo en cuenta la importancia de
garantizar el acceso en el futuro. Altos precios como la soluci=C3=B3n del
costeo de la innovaci=C3=B3n no es la soluci=C3=B3n.
=09=C2=B7 La manutenci=C3=B3n y ampliaci=C3=B3n de la particip=
aci=C3=B3n
de las organizaciones de la sociedad civil y de pacientes,
especialmente aquellos del Sur, en negociaciones realizadas en el
IGWG, considerando atentamente los conflictos de inter=C3=A9s que puedan
existir en el =C3=A1mbito de esas organizaciones.
[1] Data estimates taken from the IMS website.
[2] http://www.who.int/intellectualproperty/en/ [4]
=09Firma de las organizaciones de la sociedad civil y grupos de
pacientes:*****************************************************************=
***************************************************************************=
***************************************************************************=
************
=091 =E2=80=93 Associa=C3=A7=C3=A3o Brasileira Interdisciplinar de AIDS - A=
BIA (RJ -
Brasil)
2 =E2=80=93 Grupo de Incentivo =C3=A0 Vida - GIV (SP - Brasil)
3 =E2=80=93 Grupo de Apoio aos Doentes de AIDS Solid=C3=A1rio pela Vida (E=
S -
Brasil)
4 =E2=80=93 Grupo de Trabalho em Preven=C3=A7=C3=A3o Posithiva - GTP+ (Bra=
sil)
5 =E2=80=93 Articula=C3=A7=C3=A3o AIDS em Pernambuco (Brasil)
6 =E2=80=93 G=C3=AAnero, mulher, Desenvolvimento e A=C3=A7=C3=A3o para a C=
idadania -
GEMDAC (Piau=C3=AD - Brasil)
7 =E2=80=93 Centro Dialogo (Piau=C3=AD - Brasil)
8 =E2=80=93 F=C3=B3rum de ONGs/AIDS do Piau=C3=AD (Brasil)
9 =E2=80=93 F=C3=B3rum de ONGs/AIDS de Pernambuco (Brasil)
10 =E2=80=93 Rede Nacional de Pessoas Vivendo com HIV/AIDS do Nordeste
(RNP+/NE) (Brasil)
11 =E2=80=93 GAPA/SP (Brasil)
12 =E2=80=93 GAPA/RS (Brasil)
13 =E2=80=93 F=C3=B3rum Catarinense de ONGs/AIDS (Brasil)
14 =E2=80=93 F=C3=B3rum de ONGs/AIDS do Rio Grande do Norte (Brasil)
15 =E2=80=93 Comiss=C3=A3o de Articula=C3=A7=C3=A3o com Movimentos Sociais=
=E2=80=93 Regi=C3=A3o
Norte (CAMS) (Brasil)
16 =E2=80=93 F=C3=B3rum de ONGs/AIDS do Tocantins (Brasil)
17 =E2=80=93 GAPA/DF (Brasil)
18 =E2=80=93 Casa Servo de Deus (ES - Brasil)
19 =E2=80=93 GESTOS/PE (Brasil)
20 =E2=80=93 F=C3=B3rum de ONGs/AIDS da Para=C3=ADba (Brasil)
21 =E2=80=93 Grupo Solidariedade (MG) (Brasil)
22 =E2=80=93 F=C3=B3rum Mercosul
23 =E2=80=93 Grupo Pela Vidda/RJ (Brasil)
24 =E2=80=93 Organiza=C3=A7=C3=A3o Brasileira de Apoio Filantr=C3=B3pico (=
OBRAF-SP)
(Brasil)
25 =E2=80=93 Somos =E2=80=93 Comunica=C3=A7=C3=A3o, Sa=C3=BAde e Sexualida=
de (Brasil)
26 =E2=80=93 Centro de Promo=C3=A7=C3=A3o da Sa=C3=BAde (CEDAPS-RJ) (Brasi=
l)
27 =E2=80=93 F=C3=B3rum de ONGs/AIDS do Rio de Janeiro (Brasil)
28 =E2=80=93 Grupo de Apoio aos Soropositivos (GASP-MG) (Brasil)
29 =E2=80=93 F=C3=B3rum de ONGs/AIDS do Matogrosso (Brasil)
30 =E2=80=93 RNP+ N=C3=BAcleo M=C3=A9dio Para=C3=ADba (Brasil)
31 =E2=80=93 N=C3=BAcleo de Estudos da Prostitui=C3=A7=C3=A3o (NESP-RS) (B=
rasil)
32 =E2=80=93 Grupo Pela Vidda/SP (Brasil)
33 =E2=80=93 Conectas Direitos Humanos (Brasil)
34 =E2=80=93 Instituto de Defesa do Consumidor (IDEC-SP) (Brasil)
35 =E2=80=93 Grupo Pela Vidda/Niter=C3=B3i (Brasil)
36 =E2=80=93 M=C3=A9dicos sem Fronteiras =E2=80=93 BRASIL
37 =E2=80=93 AFADA (Araruama/RJ) (Brasil)
38 =E2=80=93 Grupo Amigos Posithivos (Brasil)
39 =E2=80=93 API-AIDS (Brasil)
40 =E2=80=93 CAAIDS (RJ) (Brasil)
41 =E2=80=93 CEDOICOM (Brasil)
42 =E2=80=93 Centro Social Cultural Tatiane Lima (Brasil)
43 =E2=80=93 Centro de Integra=C3=A7=C3=A3o, A=C3=A7=C3=A3o e Desenvolvime=
nto Social
(CIADS-RJ) (Brasil)
44 =E2=80=93 Cidade Viva (Brasil)
45 =E2=80=93 Cieds (Brasil)
46 =E2=80=93 Conselho de Gestores Comunit=C3=A1rios (Congesco-RJ) (Brasil)
47 =E2=80=93 Centro de Refer=C3=AAncia para Sa=C3=BAde da Mulher (CRESAM-R=
J)
(Brasil)
48 =E2=80=93 Federa=C3=A7=C3=A3o de Bandeirantes do Brasil (Brasil)
49 =E2=80=93 Grupo de Apoio ao Tratamento para AIDS do Hospital de Ipanema
(GATAHI-RJ) (Brasil)
50 =E2=80=93 Grupo =C3=81gua Viva (RJ) (Brasil)
51 =E2=80=93 Grupo Arco-=C3=8Dris (RJ) (Brasil)
52 =E2=80=93 Grupo Amigos Posithivos (RJ) (Brasil)
53 =E2=80=93 Grupo Assistencial SOS Vida (RJ) (Brasil)
54 =E2=80=93 Grupo de Mulheres Felipa de Souza (RJ) (Brasil)
55 =E2=80=93 Grupo Diversidade de Niter=C3=B3i (RJ) (Brasil)
56 =E2=80=93 Grupo Fio da Alma (RJ) (Brasil)
57 =E2=80=93 Grupo Reagir Posithivo (RJ) (Brasil)
58 =E2=80=93 Ibiss (RJ) (Brasil)
59 =E2=80=93 Comunidade Internacional de Mulheres Vivendo com HIV/AIDS
(ICW-BRASIL)
60 =E2=80=93 Instituto Evang=C3=A9lico de Assist=C3=AAncia M=C3=A9dica e S=
ocial (RJ)
(Brasil)
61 =E2=80=93 Milagre da Vida (RJ) (Brasil)
62 =E2=80=93 Movimento Nacional Cidad=C3=A3s Positivas (RJ) (Brasil)
63 =E2=80=93 Movimento de Mulheres de S=C3=A3o Gon=C3=A7alo (RJ) (Brasil)
64 =E2=80=93 Ser Mulher (RJ) (Brasil)
65 - Thai network of people living with HIV/AIDS (TNP+ - Tail=C3=A2ndia)
66 - Thai Rural Doctors society (Tail=C3=A2ndia)
67 - Rural Pharmacist Foundation (Tail=C3=A2ndia)
68 - Thai NGOs Coalition on AIDS (Tail=C3=A2ndia)
69 - Foundation for AIDS Rights (FAR - Tail=C3=A2ndia)
70 - AIDS ACCESS Foundation (Tail=C3=A2ndia)
71 - Foundation for consumers (Tail=C3=A2ndia)
72 - Federa=C3=A7=C3=A3o Nacional dos Farmac=C3=AAuticos (Fenafar) (Brasil=
)
73 =E2=80=93 Grupo de Resist=C3=AAncia Asa Branca-GRAB (Brasil)
74 =E2=80=93 Rede de Solidariedade Positiva-RSP+ (Brasil)
75 =E2=80=93 Nacional de Pessoas Vivendo com HIV/Aids- n=C3=BAcleo Cear=C3=
=A1
(Brasil)
76 =E2=80=93 Movimento de Reintegra=C3=A7=C3=A3o das Pessoas Atingidas pel=
a
Hansen=C3=ADase (MORHAN) - Fortaleza (Brasil)
77 =E2=80=93 Associa=C3=A7=C3=A3o dos Volunt=C3=A1rios do hospital S=C3=A3=
o Jos=C3=A9 (Brasil)
78 =E2=80=93 N=C3=BAcleo de Integra=C3=A7=C3=A3o pela Vida-NIV (Brasil)
79 =E2=80=93 Misi=C3=B3n Salud (Colombia)
80 =E2=80=93 Acci=C3=B3n Internacional por la Salud (Colombia)
81 =E2=80=93 Fundaci=C3=B3n IFARMA (Colombia)
82 - Red Colombiana de Personas Con VIH o SIDA =E2=80=93 RECOLVIH
(Colombia)
83 =E2=80=93 Oxfam International - Brasil
84- Action Aid International
85- Agua Buena Pro Defensa de DDHH (Costa Rica)
86- Caribbean Vulnerable Communities Coallition - CVC (Caribbean)
87- Centro de Orientaci=C3=B3n e Investigaci=C3=B3n Integral =E2=80=93 COI=
N
(Republica Dominicana)
88- Amigos Siempre Amigos (Republica Dominicana)
89- Acci=C3=B3n Ciudadana Contra el Sida (Venezuela)
90- Laccaso/ Consejo Latino Americano y del Caribe de Organizaciones
con Servicios en VIH/Sida
91 - Centre for Trade and Development =E2=80=93 Centad (India)
92 - Delhi Network of Positive People =E2=80=93 DNP+ (India)
93 - Positive Malaysian Treatment Access & Advocacy Group - MTAAG+
(Malaysia)
94 - Positive Living/ PT Foundation (Malaysia)
95 - Network of Indian People with Alternative Sexuality Living with
HIV/Aids =E2=80=93 NIPASHA+ (India)
96 - Health GAP
97 - Korean Federation of Medical Groups for Health Rights =E2=80=93 KFHR
(Korea)
98 - Physicians` Association for Humanism (Korea)
99 - Aids Law Project =E2=80=93 ALP (South Africa)
100 - Treatment Action Campaign =E2=80=93 TAC (South Africa)
101 - AIRO + Rights Alliance for Southern Africa =E2=80=93 ARASA (South
Africa)
-------------------------
Links:
------
[1]
http://www.patientsandpatents.com/index.php/us/positions/patient_declaratio=
n_on_medical_innovation
[2] http://www.who.int/intellectualproperty/en/
[3] http://www.who.int/intellectualproperty/en/
[4] http://www.who.int/intellectualproperty/en/
--
[ Carta_IGWG_3idiomas_abril2008.pdf of type application/octet-stream delete=
d ]
--